NP also said High 100's, with that though, there are not many out there that could afford us. Unless they did one hell of a stock deal with money per share.. Solid Tumor Cancer is 120 Billion a year market. If we only get half the market, that is over 85 a share, and we have indications in 30+ illnesses?! Heck, look at NASH or its precursor - NAFLD. 80 million to 100 million in the US alone affected. Use Leronlimab as a preventative before NASH sets in, the numbers are astronomical, even if you had 1/4 of the patients on it, you would still be 850 dollars a share, just for NAFLD/NASH. The numbers are so insanely high, that I do not even know how you would calculate a fair price for buyout.

P.S. My numbers were calculated using the lower amount of 30k a year... Still no clear idea what the number will be since it is changing all the time.